Abstract
Diabetes, dyslipidemia and hypertension are important metabolic diseases that impose a great burden on many populations worldwide. However, certain population strata have reduced prevalence for all three diseases, but the underlying mechanisms are poorly understood. We sought to identify the phenotypic, genomic and metabolomic characteristics of the low-prevalence population to gain insights into possible innate non-susceptibility against metabolic diseases. We performed k-means cluster analysis of 16,792 subjects using anthropometric and clinical biochemistry data collected by the Taiwan Biobank. Nuclear magnetic resonance spectra-based metabolome analysis was carried out for 217 subjects with normal body mass index, good exercise habits and healthy lifestyles. We found that the gene APOA5 was significantly associated with reduced prevalence of disease, and lesser associations included the genes HIF1A, LIMA1, LPL, MLXIPL, and TRPC4. Blood plasma of subjects belonging to the low disease prevalence cluster exhibited lowered levels of the GlycA inflammation marker, very low-density lipoprotein and low-density lipoprotein cholesterol, triglycerides, valine and leucine compared to controls. Literature mining revealed that these gen...Continue Reading
References
Apr 20, 2004·The Journal of Biological Chemistry·Frank G SchaapKo Willems van Dijk
Sep 15, 2005·Circulation·Scott M GrundyUNKNOWN National Heart, Lung, and Blood Institute
Aug 26, 2006·Nature Clinical Practice. Cardiovascular Medicine·Rebecca L Pollex, Robert A Hegele
Dec 15, 2006·Nature·Gökhan S Hotamisligil
Feb 16, 2008·Molecular Systems Biology·Ville-Petteri MäkinenMika Ala-Korpela
Mar 28, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·W Ray KimUNKNOWN Public Policy Committee of the American Association for the Study of Liver Disease
May 21, 2008·Endocrine Journal·Katsumi Iizuka, Yukio Horikawa
Apr 10, 2009·The European Respiratory Journal·M WeatherallR Beasley
Dec 17, 2010·World Journal of Cardiology·Temilolu Olayinka Aje, Michael Miller
Mar 2, 2011·PloS One·Nikolaos PsychogiosDavid S Wishart
Jun 3, 2011·Obesity·Altan OnatYüksel Doğan
Sep 3, 2011·Nature·Karsten SuhreChristian Gieger
Oct 6, 2011·The Biochemical Journal·Guo-Min ShenJun-Wu Zhang
Jan 28, 2012·Experimental Biology and Medicine·Sarabeth GrahamRong Ma
Aug 15, 2012·Immunological Reviews·Adam T Waickman, Jonathan D Powell
Feb 19, 2013·Annals of Intensive Care·Myriam TavernaBertrand Guidet
Mar 26, 2013·PloS One·Nancy BabioUNKNOWN PREDIMED Study Investigators
Aug 5, 2014·The Journal of Clinical Hypertension·Debbie L CohenDonald J DiPette
Jan 13, 2015·Mathematical Medicine and Biology : a Journal of the IMA·Ralph Brinks, Sandra Landwehr
Feb 19, 2015·Circulation. Cardiovascular Genetics·Pasi SoininenMika Ala-Korpela
Mar 18, 2015·Clinical Chemistry·James D OtvosRussell P Tracy
Jan 1, 2014·Clinical Epigenetics·Aida ZarfeshaniAllan M Sheppard
May 15, 2015·Diabetes·Christiane L HaaseRuth Frikke-Schmidt
Dec 26, 2015·European Journal of Internal Medicine·Mehmet KanbayRichard J Johnson
Feb 16, 2016·Nature Reviews. Genetics·William S BushDana C Crawford
Apr 9, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jonathan D SchofieldHandrean Soran
Jul 7, 2016·Scientific Reports·Lovro ZibernaSabina Passamonti
Nov 1, 2016·Human Molecular Genetics·Chien-Hsiun ChenChen-Yang Shen
Mar 8, 2017·Scientific Reports·Qi GuoGang Wang
Jun 9, 2018·Science·Ying-Yu ZhangBao-Liang Song
Jul 11, 2018·Nature Medicine·Fernando OvalleAnath Shalev
Nov 6, 2018·JCI Insight·J Humberto Treviño-VillarrealJames R Mitchell